Roche Inks $549M Deal To License 'Superbug' Antibiotic

Law360, New York (November 4, 2013, 2:43 PM EST) -- Biotech giant Roche will pay up to 500 million Swiss francs ($549 million) to Polyphor Ltd. for an exclusive worldwide license agreement to develop and market its drug that targets an antibiotic-resistant "superbug" bacteria often found in hospitals, according to a statement.

Roche, under the deal terms, will make an initial payment of 35 million Swiss francs followed by payments based on development, regulatory and commercial milestones of the POL7080 antibiotic, according to a statement. Polyphor will also receive tiered royalties on product sales and will...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.